TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06081556

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonic testing
Description: mean gestational sac diameter（mGSD）, crown-rump length （CRL）, mGSD-CRL, D-dimer (DD), adenosine diphosphate (ADP), arachidonic acid (AA), and the ratio of uterine artery peak systolic value to end-diastolic value (UtA-S/D) were collected

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonic testing
Description: mean gestational sac diameter（mGSD）, crown-rump length （CRL）, mGSD-CRL, D-dimer (DD), adenosine diphosphate (ADP), arachidonic acid (AA), and the ratio of uterine artery peak systolic value to end-diastolic value (UtA-S/D) were collected

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonic testing
Description: mean gestational sac diameter（mGSD）, crown-rump length （CRL）, mGSD-CRL, D-dimer (DD), adenosine diphosphate (ADP), arachidonic acid (AA), and the ratio of uterine artery peak systolic value to end-diastolic value (UtA-S/D) were collected
Study: NCT02416284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NFBDG
Description: Intervention consists of:~Lecture presenting the NFBDG, Printed booklet containing the NFBDG, Suggested meal plan for a week, Recipes, Access to a restricted website with further information on the NFBDG, A Facebook-group where Vegetable of the day was presented with a suggested recipe, text-messages with encouragement to follow the guidelines, follow-up phone-calls, common exercise sessions, Free common meals (1 breakfast, 2 lunches, 1 dinner), Free foods (low-fat dairy products, a juice containing grapes, blueberries, chokeberries, and cherries and fruits)
Study: NCT01469858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Siemens magnetom avanto1.5 Tesla, Siemens magnetom trio A Tim system 3 Tesla
Description: functional magnetic resonance imaging
Study: NCT00480610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus ointment
Description: Topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment
Description: Topical application
Study: NCT04477681

Intervention type: OTHER
Intervention: Data collection
Description: In particular, the patient's demographic data, medical history, previous and concomitant treatments, data on the treatment of interest (legal framework, compassionate use/ off-label), dosage, start date, etc.), clinical data will be collected. biological (including molecular profiling of the tumor if available) and radiological follow-up, information on adverse effects. The data to be filled in is that of the CERFA pharmacovigilance form of the ANSM, but additional fields can be created if necessary.
Study: NCT01683201

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional exercise class
Description: Functional exercise class running twice weekly for six weeks from week 12 to week 18

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: usual care group
Description: Usual care group adhere to post operative instructions given on discharge from hospital
Study: NCT04220996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine 10 and 20 mg/day, tablets, orally Patients will receive 10 mg vortioxetine once daily for the first week. At Visit 2, the dose will be increased to 20 mg/day. The dose may subsequently be adjusted to 10 or 20 mg/day at scheduled or unscheduled visits depending on patient's response as per investigator judgment.
Study: NCT02652897

Intervention type: PROCEDURE
Intervention: Exposure to glioma resection surgery
Description: The following blood samples will be drawn for hemostasis evaluation: 1. Conventional clotting tests, 2. Rotational thromboelastometry (ROTEM), including EXTEM and FIBTEM; 3. Platelet function as assessed by PFA-200 for; and 4. Platelet function as assessed by ara-tem, adp-tem and trap-tem. All the analyses will be performed before (within a period 24-h before surgery) and after (within of the following periods: 2 h, 24 h and 48 h after surgery).

Intervention type: PROCEDURE
Intervention: Exposure to colon resection surgery
Description: The following blood samples will be drawn for hemostasis evaluation: 1. Conventional clotting tests, 2. Rotational thromboelastometry (ROTEM), including EXTEM and FIBTEM; 3. Platelet function as assessed by PFA-200 for; and 4. Platelet function as assessed by ara-tem, adp-tem and trap-tem. All the analyses will be performed before (within a period 24-h before surgery) and after (within of the following periods: 2 h, 24 h and 48 h after surgery).
Study: NCT03678597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium Supplemented with Latrunculin B
Description: A medium with in-house supplementation of Latrunculin B to decrease oocyte degeneration after ICSI and improve the survival rate
Study: NCT02766829

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cross leg sitting position
Description: Subjects were set on cross leg sitting position before spinal anesthesia begun.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional sitting position
Description: Subjects were set on traditional sitting position before spinal anesthesia begun.
Study: NCT03739450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Training (PST)
Description: The PST intervention consists of six sessions that will follow a structured format based on the PST manual. In these sessions, the interventionist will first provide the TBI-specific education, introduce the participant to the PST steps, then help the care partner generate and select a problem to address first. Interventionist will facilitate the care partner's use of the ABCDEF steps of PST to develop a specific action plan to solve the problem. As problems are attempted or solved, the care partner will learn how to perform the steps on his/her own, thus acquiring self-management problem solving skills that will be applicable to future problems. The final session will include a review and generalization of the PST steps and progress made.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants will receive TBI-specific education alone through a workbook. It consists of educational modules for self-study, common sequelae of TBI, issues encountered by care partners, work and school concerns for those with TBI, and on navigating the rehab system and accessing resources. The modules consist of a brief introduction, key definitions, examples, resources, and a summary. Some chapters also include self-directed activities, such as worksheets or checklists. The investigators will provide a brief orientation to the workbook and include open-ended questions about the participants' need for clarification or questions of the education material. The last session will consist of an open discussion about expected problems that may arise post-discharge.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants will receive TBI-specific education alone through a workbook. It consists of educational modules for self-study, common sequelae of TBI, issues encountered by care partners, work and school concerns for those with TBI, and on navigating the rehab system and accessing resources. The modules consist of a brief introduction, key definitions, examples, resources, and a summary. Some chapters also include self-directed activities, such as worksheets or checklists. The investigators will provide a brief orientation to the workbook and include open-ended questions about the participants' need for clarification or questions of the education material. The last session will consist of an open discussion about expected problems that may arise post-discharge.
Study: NCT01495442

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: modified Handihaler DPI
Description: subjects randomized to receive 1 inhaled dose on 2 separate days, each dose delivered 2-3 days apart. The radiolabeled albuterol drug powder will be dispersed from either the DET bead-HandiHaler prototype or via the established HandiHaler device standard with the lactose-albuterol formulation provided to us by the sponsor.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: standard Handihaler DPI
Description: subjects randomized to receive 1 inhaled dose on 2 separate days, each dose delivered 2-3 days apart. The radiolabeled albuterol drug powder will be dispersed from either the DET bead-HandiHaler prototype or via the established HandiHaler device standard with the lactose-albuterol formulation provided to us by the sponsor.
Study: NCT03483480

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NPWT for Pilonidal Surgery
Description: After excision of pilonidal sinus Non powered-NPWT will be applied to the area

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Excision of Pilonidal sinus with normal dressing
Description: After excision of pilonidal sinus normal dressing will be applied to the area of surgery
Study: NCT03354754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYS228
Description: LYS228 IV infusion every 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care therapy
Description: IV infusion of standard of care antibiotics
Study: NCT00935168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6% Hydroxy-ethyl starch (130/0.4)
Description: Maximum dose of 50ml/kg/day of 6% hydroxy-ethyl starch (130/0.4) for intravascular volume fluid resuscitation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Maximum dose of 50ml/kg/day of saline for intravascular volume fluid resuscitation
Study: NCT02365168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cod_Double Blind Placebo Controlled Food Challenge
Description: DBPCFC Food Challenge with cod in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salmon_Double Blind Placebo Controlled Food Challenge
Description: DBPCFC Food Challenge with salmon in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mackerel_Double Blind Placebo Controlled Food Challenge
Description: DBPCFC Food Challenge with mackerel in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo_Double Blind Placebo Controlled Food Challenge
Description: DBPCFC Food Challenge with placebo covered in chocholate dessert over one day
Study: NCT01958801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supraclavicular block
Description: Redirection of the needle is allowed when spread of local anesthetics does not surround the brachial plexus appropriately and involuntary movement of the forearm or hand is not necessary to confirm the correct placement of the needle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block
Description: Redirection of the needle is allowed when spread of local anesthetics does not surround the brachial plexus appropriately and involuntary movement of the forearm or hand is not necessary to confirm the correct placement of the needle.
Study: NCT03607864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coral bone graft and xenograft
Description: ligible patients will be randomized in equal proportions between control group(immediate implant placement with grafting with xenograft) and study group (immediate implant placement with grafting with coral bone) Patients of both groups will be subjected to standard panoramic radiographs, cone beam ct .~Crestal bone level will measured by cone beam ct. Local anesthesia will be given to the patient. Only sulcular incision line with reflection is used A peritome will be used for a traumatic extraction of remaining roots. The extraction socket will be evaluated for absence of any fenestration or granulation tissues implant will be inserted in extraction socket bodily palatal with grafting with coral bone and xenograft The flap will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 5/0 prolene sutures.
Study: NCT04033835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentalization Based Treatment-Introductory
Description: Mentalization Based Treatment-Introductory

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual
Study: NCT02778230

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Control
Description: Snacks (2 baked goods) without fiber fortification.
Study: NCT02235532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foramen Herbal Aloe toothpaste
Description: use of aloe-vera toothpaste for 30 days in the test group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fluoride toothpaste
Description: use of signal toothpaste once a day for 30 days in the control group.
Study: NCT00992316

Intervention type: DRUG
Intervention: PF-04531083
Description: solution. doses to be selected based upon safety/tolerability/PK at preceeding dose
Study: NCT00699517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMBRABULIN (AVE8062)
Description: I.V. infusion followed by administration of cisplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: I.V. infusion followed by administration of cisplatin
Study: NCT00917449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine
Description: Oral L-arginine (3.2 gr bid)for 18 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo BID for 18 months
Study: NCT02921971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR156597
Description: Pharmaceutical form: Solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution Route of administration: Subcutaneous
Study: NCT00326898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study: NCT02503904

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant Tumescent Antibiotic Delivery & IV Delivery
Description: Concomitant subcutaneous infiltration of a dilute antibiotics (cefazolin and metronidazole) in a dilute solution of tumescent lidocaine and epinephrine at the site of a proposed surgical incision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant Tumescent Antibiotic Delivery & IV Delivery
Description: Concomitant subcutaneous infiltration of a dilute antibiotics (cefazolin and metronidazole) in a dilute solution of tumescent lidocaine and epinephrine at the site of a proposed surgical incision.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Tumescent Infiltration
Description: Subcutaneous tumescent infiltration using HK tumescent infiltration cannulas and HK tumescent infiltration pump

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cecefazolin and metronidazole (in a dilute solution of tumescent lidocaine, epinephrin and sodium bicarbonate in 0.9% physiologic saline)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cecefazolin and metronidazole (in a dilute solution of tumescent lidocaine, epinephrin and sodium bicarbonate in 0.9% physiologic saline)
Study: NCT02953535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magicbuvir
Description: 1 tablet contains 400 mg sofosbuvir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sovaldi (fist dose)
Description: 1 tablet contains 400 mg sofosbuvir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sovaldi (second dose)
Description: 1 tablet contains 400 mg sofosbuvir
Study: NCT00493870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 IV over 1 hour on Day 1 followed by cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 IV over 1 hour on Day 1 followed by cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: • Doxorubicin 50 mg/m2 IV push over 5-15 minutes via sidearm through a running IV line on Day 1, followed by cyclophosphamide 500 mg/m2 IV over 15-30 minutes on Day 1, followed by docetaxel 75 mg/m2 IV over 1 hour on Day 1. Administer pegfilgrastim 6 mg SC on Day 2 (or filgrastim 5 mcg/kg SC per standard of care).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV over 15-30 minutes on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV over 15-30 minutes on Day 1.
Study: NCT02211274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Everyday Competence Assessment and Planning for Community Transitions
Description: The Everyday Competence Assessment and Planning for Community Transitions (ECAP-CT) toolkit will allow CLC interdisciplinary team members to 1) assess the Veteran's everyday competence for safe and independent living; 2) develop personally meaningful rehabilitation goals that facilitate successful transition out of the CLC based on everyday competence; and 3) conduct structured treatment planning to support resident goals around transitioning back into the community. By considering everyday competence and goal-setting in this context, Veterans will have optimal P-E fit upon returning to the community, ensuring a successful transition.
Study: NCT03294018

Intervention type: OTHER
Intervention: Recording heart rate changes
Description: Recording heart rate changes during planned sugammadex administration.
Study: NCT02236455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio Relaxation Technique
Description: Audio relaxation technique created by an Icelandic Registered Nurse.
Study: NCT01666470

Intervention type: OTHER
Intervention: Questionnaires
Description: DrHy-Q (Thai version) and WHOQOL-BREF-THAI will be asked
Study: NCT04072380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUVN-G3031
Description: SUVN-G3031 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUVN-G3031
Description: SUVN-G3031 Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tablets
Study: NCT02750826

Intervention type: OTHER
Group type: OTHER
Intervention: Health Education Program

Intervention type: OTHER
Group type: OTHER
Intervention: Health Education Program

Intervention type: OTHER
Group type: OTHER
Intervention: Weight Loss Intervention
Study: NCT02236455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Music Intervention
Description: Audio recordings of non-lyrical relaxing music

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nature Therapy without Music
Description: Nature videos of the mountains, desert, Icelandic scenery, and ocean were provided via iPads for surgical patients

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nature Therapy with Music
Description: Nature videos of the mountains, forest, Icelandic landscape, and the ocean were provided via iPads for surgical patients
Study: NCT01002807

Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, Single Dose

Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, Single Dose

Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, Single Dose

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin XR
Description: Tablets, Oral, 1000 mg, Single Dose

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin XR
Description: Tablets, Oral, 1000 mg, Single Dose

Intervention type: DRUG
Group type: OTHER
Intervention: Glucophage
Description: Tablets, Oral, 1000 mg, Single Dose
Study: NCT01017393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine free
Study: NCT01726751

Intervention type: DEVICE
Group type: OTHER
Intervention: Spinal Cord Stimultion (SCS)
Description: Electric stimulation of the spinal cord

Intervention type: DEVICE
Group type: OTHER
Intervention: Spinal Cord Stimultion (SCS)
Description: Electric stimulation of the spinal cord

Intervention type: DEVICE
Group type: OTHER
Intervention: Spinal cord nerve stimulation

Intervention type: DEVICE
Group type: OTHER
Intervention: Spinal cord nerve stimulation
Study: NCT02346760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UB-621
Description: 100 mg/ml, subcutaneous injection
Study: NCT01908647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RT fMRI
Description: Real-time fMRI with neurofeedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RT fMRI
Description: Real-time fMRI with neurofeedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Computer based attention training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Computer based attention training.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control RT fMRI
Description: Control condition for real-time fMRI.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control RT fMRI
Description: Control condition for real-time fMRI.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Cognitive Training
Description: Computer-based games used as a control for the computer based cognitive training intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Cognitive Training
Description: Computer-based games used as a control for the computer based cognitive training intervention.